ONO Pharmaceutical Overview
- Year Founded
-
1947
- Status
-
Public
- Employees
-
4,287
- Stock Symbol
-
4528
- Investments
-
5
- Share Price
-
$15.57
- (As of Thursday Closing)
ONO Pharmaceutical General Information
Description
Ono Pharmaceutical Co Ltd is a drug manufacturer with a focus on drug discovery in areas of unmet medical needs. The vast majority of the company's revenue is derived from its circulatory and respiratory drugs, followed by its metabolic drugs and vitamins. The company also reports revenue derived from royalties. The bulk of the company's sales is generated in Japan, followed by the rest of Asia and Europe.
Contact Information
Website
www.ono-pharma.comCorporate Office
- 8-2, Kyutaromachi 1-chome
- Chuo-ku
- Osaka, 541-8564
- Japan
Corporate Office
- 8-2, Kyutaromachi 1-chome
- Chuo-ku
- Osaka, 541-8564
- Japan
ONO Pharmaceutical Stock Performance
As of 12-Nov-2026, ONO Pharmaceutical’s stock price is $15.57. Its current market cap is $7.32B with 470M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $15.57 | $15.27 | $12.78 - $17.16 | $7.32B | 470M | 1.71M | $1.01 |
ONO Pharmaceutical Financials Summary
As of 30-Sep-2026, ONO Pharmaceutical has a trailing 12-month revenue of $3.12B.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2026 31-Mar-2026 | FY 2025 31-Mar-2025 | FY 2024 31-Mar-2024 |
|---|---|---|---|---|
| EV | 6,380,860 | 7,009,652 | 4,948,057 | 6,799,345 |
| Revenue | 3,120,734 | 3,422,029 | 3,192,636 | 3,478,944 |
| EBITDA | 859,872 | 862,425 | 568,964 | 1,232,447 |
| Net Income | 474,051 | 462,876 | 328,181 | 885,716 |
| Total Assets | 6,933,056 | 6,921,862 | 7,110,594 | 6,036,789 |
| Total Debt | 698,709 | 756,515 | 980,190 | 58,553 |
ONO Pharmaceutical Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
ONO Pharmaceutical Comparisons
Industry
Financing
Details
ONO Pharmaceutical Competitors (21)
One of ONO Pharmaceutical’s 21 competitors is Chugai Pharmaceutical, a Corporate Backed or Acquired company based in Tokyo, Japan.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Chugai Pharmaceutical | Corporate Backed or Acquired | Tokyo, Japan | ||||
| Sanofi | Corporation | Gentilly, France | ||||
| Aytu Biopharma | Corporation | Denver, CO | ||||
| Evonile Pharma | Private Equity-Backed | Mumbai, India | ||||
| Torrent Pharmaceuticals | Corporation | Ahmedabad, India |
ONO Pharmaceutical Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
ONO Pharmaceutical Patents
ONO Pharmaceutical Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| JP-7799944-B1 | Display control method, program, and information processing device | Active | 07-Aug-2025 | ||
| JP-7769895-B1 | Display control method, program, and information processing device | Active | 26-Jun-2025 | ||
| WO-2026191963-A1 | Mesothelin targeting agent | Pending | 12-Mar-2025 | ||
| WO-2026173107-A1 | Sulfonamide derivative | Pending | 17-Feb-2025 | ||
| JP-2026133357-A | Computer programs and management servers | Pending | 06-Feb-2025 |
ONO Pharmaceutical Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
ONO Pharmaceutical Investments & Acquisitions (5)
ONO Pharmaceutical’s most recent deal was a Later Stage VC with Healx for . The deal was made on 01-Aug-2024.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Healx | 01-Aug-2024 | Later Stage VC | Discovery Tools (Healthcare) | ||
| Deciphera Pharmaceuticals | 11-Jun-2024 | Merger/Acquisition | Drug Discovery | ||
| Rehab for JAPAN | 24-May-2021 | Later Stage VC | Elder and Disabled Care | ||
| Ribon Therapeutics (Patented Solid Tumors Treatments) | 02-Feb-2021 | Corporate Asset Purchase | Buildings and Property | ||
| Numab Therapeutics | 09-Mar-2020 | Later Stage VC | Drug Discovery |
ONO Pharmaceutical ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
23.23 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,585
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Pharmaceuticals
Subindustry
of 354
Rank
Percentile
ONO Pharmaceutical Affiliates
Subsidiaries (7)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Ono Digital Health Investment | Chuo-ku, Japan | 2022 | |
| Ono Venture Investment | San Francisco, CA | 2020 | |
| Deciphera Pharmaceuticals | Waltham, MA | 2003 | |
| Ono Pharma Uk | London, United Kingdom | 1998 | |
| Kk Beebrand Medico Dental | Osaka, Japan | 1982 |
ONO Pharmaceutical FAQs
-
When was ONO Pharmaceutical founded?
ONO Pharmaceutical was founded in 1947.
-
Where is ONO Pharmaceutical headquartered?
ONO Pharmaceutical is headquartered in Osaka, Japan.
-
What is the size of ONO Pharmaceutical?
ONO Pharmaceutical has 4,287 total employees.
-
What industry is ONO Pharmaceutical in?
ONO Pharmaceutical’s primary industry is Drug Delivery.
-
Is ONO Pharmaceutical a private or public company?
ONO Pharmaceutical is a Public company.
-
What is ONO Pharmaceutical’s stock symbol?
The ticker symbol for ONO Pharmaceutical is 4528.
-
What is the current stock price of ONO Pharmaceutical?
As of 12-Nov-2026 the stock price of ONO Pharmaceutical is $15.57.
-
What is the current market cap of ONO Pharmaceutical?
The current market capitalization of ONO Pharmaceutical is $7.32B.
-
What is ONO Pharmaceutical’s current revenue?
The trailing twelve month revenue for ONO Pharmaceutical is $3.12B.
-
Who are ONO Pharmaceutical’s competitors?
Chugai Pharmaceutical, Sanofi, Aytu Biopharma, Evonile Pharma, and Torrent Pharmaceuticals are some of the 21 competitors of ONO Pharmaceutical.
-
What is ONO Pharmaceutical’s annual earnings per share (EPS)?
ONO Pharmaceutical’s EPS for 12 months was $1.01.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
